BRIEF—Gilead Sciences appoints new chief medical officer

Gilead Sciences has appointed Merdad Parsey as chief medical officer. Dr Parsey joins Gilead from Roche subsidiary Genentech, where he is senior vice president of early clinical development.

He has clinical expertise across therapeutic areas, including inflammation, oncology and infectious diseases.

Prior to his most recent tenure with Genentech, Dr Parsey served as president and chief executive of 3-V Biosciences, and has had development roles at Sepracor, Regeneron and Merck & Co.